Efficacy of MtH2SDs in Duchenne muscular dystrophy (DMD)

Project Member(s): Hansbro, P.

Funding or Partner Organisation: Mitorx Therapeutics
Mitorx Therapeutics

Start year: 2022

Summary: Primary Aim: Assess the efficacy of lead and follower MtH2SD compounds in slowing loss of function and histological decline in limb skeletal muscle, respiratory muscle, and cardiac muscle in male D2.mdx vs. male D2 mouse. Secondary Aim: Proteomic, transcriptomic, lipidomic and metabolomic analysis, and storage of tissue for such analysis in support of proof-of-mechanism.

FOR Codes: Treatment of human diseases and conditions, Cardiovascular medicine and haematology

Acknowledgement of Country

UTS acknowledges the Gadigal people of the Eora Nation, the Boorooberongal people of the Dharug Nation, the Bidiagal people and the Gamaygal people, upon whose ancestral lands our university stands. We would also like to pay respect to the Elders both past and present, acknowledging them as the traditional custodians of knowledge for these lands.